MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

Completed · Phase 1/Phase 2

Conditions studied: Prostatic Neoplasms

In brief

The purpose of the study is to determine the highest dose of MLN2704 that can be given multiple times safely to patients with prostate cancer, and to identify any side effects associated with taking the drug. This study will also evaluate how MLN2704 is taken up, broken down and eliminated by the body.

Key facts

Study ID

NCT00070837

Run by

Millennium Pharmaceuticals, Inc.

People needed

46

Starts

2003-10-01

Expected to finish

2004-10-01

Last updated by the study team

2007-07-13

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologic or cytologic diagnosis (recent or remote) of prostate adenocarcinoma
• Radiographic evidence (recent or remote) of metastatic prostate adenocarcinoma
• 18 years of age or older
• Progressive prostate cancer as defined by the presence of one or more of the following despite castrate levels of testosterone (testosterone <50 ng/dL):
• Progressive tumor lesions (changes in the size of lymph nodes or parenchymal masses on physical examination or X-ray and CT scan or MRI)
• Progressive bone metastasis (presence of new lesion(s) on a bone scan)
• Progressive PSA levels (as defined in Section 3.6.1)
• Subjects who have received an anti-androgen must have shown progression of disease following discontinuation of the anti-androgen
• Subjects must remain on luteinizing hormone-releasing hormone (LHRH) analog therapy for the duration of the trial unless surgically castrate
• Agree to use an effective barrier method of contraception.

You may not qualify if…

• Testosterone >50 ng/dL
• Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of dosing
• Use of PC-SPES within 4 weeks of dosing
• Prior cytotoxic chemotherapy and/or radiation therapy within 6 weeks of dosing
• Use of anti-androgen therapy (eg, flutamide, bicalutamide, nilutamide) within 6 weeks of dosing
• Prior monoclonal antibody administration, including Prostascint®
• Peripheral neuropathy of > Grade 2, as defined by the NCI Common Toxicity Criteria for Adverse Events (NCI CTCAE)
• History of CNS metastasis, including incompletely treated epidural disease
• History of Hepatitis B or C
• History of seizure disorder requiring active treatment and/or stroke
• History of HIV infection
• Platelet count <100,000/mm3
• Absolute neutrophil count (ANC) <1,500/mm3
• Hematocrit <27 percent
• Abnormal coagulation profile (elevated PT, and/or INR, PTT)
• Serum creatinine >2.0 mg/dL, or creatinine clearance <60 mL/min if serum creatinine >2.0 mg/dL
• AST or ALT >1.5 x ULN
• Bilirubin (total) >1.25 x ULN
• Serum calcium >12.5 mg/dL
• Active serious infection not controlled by antibiotics
• Active angina pectoris or NY Heart Association Class III-IV heart disease
• Karnofsky Performance Status <60%
• Life expectancy <6 months
• Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems that might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Weill Medical College of Cornell University/ New York Presbyterian Hospital — New York, New York, United States
• Duke University Medical Center, Box 3532 — Durham, North Carolina, United States
• Cleveland Clinic, Taussig Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.